General
Preferred name
BELINOSTAT
Synonyms
PXD101 ()
NSC726630 ()
PX-105684 ()
Belinostat (PXD101) ()
A-1380 ()
PDX-101 ()
PX105684 ()
PXD101,NSC726630, PX-105684 ()
PXD-101 ()
NSC-726630 ()
Beleodaq ()
(E/Z)-Belinostat ()
P&D ID
PD003512
CAS
414864-00-9
866323-14-0
Tags
obsolete probe
natural product
drug
available
Drug Status
investigational
approved
Drug indication
Haematological malignancy
Peripheral T-cell lymphoma
Solid tumour/cancer
Max Phase
Phase 4
First approval
2014
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
TOXICITY
Belinostat is genotoxic according to Ames test and may impair male fertility. Weekly complete blood count should be monitored during treatment to adjust the dosage as intravenous infusion of belinostat is frequently associated with hematologic toxicity such as leukopenia and thrombocytopenia. Incidences of infections such as sepsis, hepatotoxicity, tumor lysis syndrome, gastrointestinal toxicity, and embryo-fetal toxicity may occur. ; No specific information is available on the treatment of overdosage of Beleodaq. There is no antidote for Beleodaq and it is not known if Beleodaq is dialyzable. If an overdose occurs, general supportive measures should be instituted as deemed necessary by the treating physician.
DESCRIPTION
Belinostat is a pan-histone deacetylase (HDAC) inhibitor .
(GtoPdb)
DESCRIPTION
inhibitor of HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8
(Informer Set)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
18
Organisms
3
Compound Sets
22
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugMAP
Guide to Pharmacology
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
Obsolete Compounds
Other bioactive compounds
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
Welcome Trust Cancer Drugs
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
40
Molecular Weight
318.07
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
2
cLogP
2.01
TPSA
95.5
Fraction CSP3
0.0
Chiral centers
0.0
Largest ring
6.0
QED
0.45
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target
HDAC1
HDAC2
HDAC3
HDAC6
HDAC8
HDAC
HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Autophagy,HDAC
Compound status
clinical
Pathway
chromain histone acetylation
Chromatin/Epigenetic
DNA Damage/DNA Repair
NF-??b
Autophagy
Cell Cycle/DNA Damage
Epigenetics
Member status
member
MOA
HDACs
Apoptosis Inducers
Histone Deacetylase 1 (HDAC1) Inhibitors
Histone Deacetylase 2 (HDAC2) Inhibitors
Angiogenesis Inhibitors
HDAC inhibitor
Indication
peripheral T-cell lymphoma (PTCL)
Therapeutic Class
Anticancer Agents
Source data
